Authors’ reply to Shah and Sahu-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Authors’ reply to Shah and Sahu

Published:2023 Issue:3 Volume:6 Page:489-490
ISSN:2590-3233
Container-title:Cancer Research, Statistics, and Treatment
language:en
Short-container-title:

Author:

John Anupa¹,Noronha Vanita¹,Singh Ajaykumar¹,Menon Nandini¹,Prabhash Kumar¹

Affiliation:

1. Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India

Publisher

Medknow

Subject

Cancer Research,Oncology (nursing),Drug Guides,Oncology

Reference11 articles.

1. Amivantamab:Is it really a game changer for EGFR exon 20 insertion mutation?;Shah;Cancer Res Stat Treat,2023

2. Amivantamab in non-small-cell lung cancer;Sahu;Cancer Res Stat Treat,2023

3. Amivantamab:A narrative drug review;John;Cancer Res Stat Treat,2023

4. EGFR exon 20 insertion in non-small-cell lung cancer;Panda;Cancer Res Stat Treat,2022

5. Epidermal growth factor receptor-mutated non-small-cell lung cancer:A primer on contemporary management;Rajendra;Cancer Res Stat Treat,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP